Pharma BD Deal Intelligence
Alnylam hops on AI train with up to $2B Inceptive partnership. Alnylam is gaining access to AI tools it hopes will speed the discovery of new RNA-based…
Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics. The deal gives Alnylam access to Inceptive's biology-trained AI…
Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive. Alnylam partnered with Inceptive to integrate generative AI into RNAi drug discovery,…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
On June 3, 2026, Alnylam Pharmaceuticals and AI biotech Inceptive (Inceptive Nucleics) — founded by former Transformer co-author Jakob Uszkoreit — formed a three-year strategic AI collaboration to apply Inceptive's generative AI / RNA foundation models to the design and screening of small interfering RNA (siRNA) molecules for Alnylam's RNAi therapeutic platform. Inceptive receives $30 million upfront in cash and equity and is eligible for preclinical, regulatory and commercial milestones bringing the deal's total potential value to up to $2 billion. The collaboration pairs Alnylam's 20+ years of proprietary siRNA data with Inceptive's foundation models to accelerate RNAi discovery productivity in support of Alnylam's 2030 strategy.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc. / Inceptive Nucleics, Inc. (this deal) | 2026 | $2.0B | 58 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) | 2019 | $21.4B | 76 |